Has Leonil Ganlim, MD received payments from drug or device companies?

Yes. Drug and device makers reported $19,069 in general payments to Leonil Ganlim, MD across 1,179 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Leonil Ganlim, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Leonil Ganlim, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Leonil Ganlim, MD

Endocrinology, Diabetes & Metabolism · Tupelo, MSNPI 1962512590

Payments from drug & device makers

$19,069in general payments, 2019–2025

Across 1,179 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$2K
Novo Nordisk$2K
Amgen$1K
Corcept Therapeutics$1K
Xeris Pharmaceuticals, Inc.$1K
Insulet Corporation$1K
plus $10K from 50 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	162	$2,162
Novo Nordisk	138	$1,700
Amgen(2 entities)	102	$1,473
Corcept Therapeutics	62	$1,228
Xeris Pharmaceuticals, Inc.	58	$1,189
Insulet Corporation	45	$1,010
Dexcom, Inc.	59	$987
Sanofi-aventis U.S. LLC	76	$947
Abbott	35	$890
Medtronic(2 entities)	45	$849
Boehringer Ingelheim	57	$722
AbbVie	46	$618
Recordati_rare_diseases_inc.	18	$527
AstraZeneca(2 entities)	28	$508
Amarin Pharma, Inc.	35	$474
Bayer	27	$446
Mannkind Corporation	20	$327
Radius Health, Inc.	18	$325
Merck	21	$278
Esperion Therapeutics, Inc.	16	$206
Sequel Med Tech, LLC	7	$180
Pfizer	10	$161
Eisai Inc.	8	$151
Tandem Diabetes Care, Inc.	8	$134
Alnylam Pharmaceuticals Inc.	7	$119
Amryt Pharma Holdings Ltd	6	$115
Boston Scientific	1	$100
BD	4	$95
Chiasma, Inc.	1	$85
RGH Enterprises LLC	2	$78
Kyowa Kirin, Inc.	4	$72
Endo Pharmaceuticals Inc.	4	$70
Sanofi	3	$68
Regeneron Healthcare Solutions, Inc.	3	$67
Ascendis Pharma Endocrinology Inc	4	$63
Neurocrine Biosciences, Inc.	2	$57
Travere Therapeutics, Inc.	5	$52
Ultragenyx Pharmaceutical Inc.	3	$52
Cequr Corporation	2	$44
Vivus LLC	4	$42
Rochester Medical Corporation	2	$42
Johnson & Johnson	2	$40
Ionis Pharmaceuticals, Inc.	2	$35
Acella Pharmaceuticals, LLC	2	$33
Shire North American Group Inc	2	$29
Lifescan, Inc.	2	$29
Kowa Pharmaceuticals America, Inc.	2	$28
Embecta Corp.	1	$22
Rhythm Pharmaceuticals, Inc.	1	$22
Novartis	1	$22
Chiesi USA, Inc.	1	$20
Madrigal Pharmaceuticals	1	$20
Ascensia Diabetes Care US Inc.	1	$17
EUSA Pharma (US) LLC	1	$16
GSK	1	$14
Azurity Pharmaceuticals, Inc.	1	$7

How this compares

$19,069 in reported general payments places this provider in the 70th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.

See all endocrinology, diabetes & metabolism providers in Mississippi →

Medicare billing

Part B allowed, 2024

$496,269

Medicare patients

1,445

Services billed

14,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Tupelo

Christy OswaltTupelo$27K
Mark ShepherdTupelo$17K
Jayant DeyTupelo$1K
Mark BorcheltGulfport$1.1M
Honey EastJackson$904K
Eric DyessJackson$885K
Ben SealeJackson$623K
Jeremy TaylorMadison$271K
Amanda SchieferJackson$204K
Delali BlavoSouthaven$148K

See the full list for Mississippi →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →